TARGIN TABLET (EXTENDED-RELEASE)

Nchi: Kanada

Lugha: Kiingereza

Chanzo: Health Canada

Viambatanisho vya kazi:

OXYCODONE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE

Inapatikana kutoka:

PURDUE PHARMA

ATC kanuni:

N02AA55

INN (Jina la Kimataifa):

OXYCODONE AND NALOXONE

Kipimo:

5.00MG; 2.50MG

Dawa fomu:

TABLET (EXTENDED-RELEASE)

Tungo:

OXYCODONE HYDROCHLORIDE 5.00MG; NALOXONE HYDROCHLORIDE 2.50MG

Njia ya uendeshaji:

ORAL

Vitengo katika mfuko:

10/14/20/28/30/50/56/60/98/100/250

Dawa ya aina:

Narcotic (CDSA I)

Eneo la matibabu:

OPIATE AGONISTS

Bidhaa muhtasari:

Active ingredient group (AIG) number: 0252684004; AHFS:

Idhini hali ya:

APPROVED

Idhini ya tarehe:

2012-06-06

Tabia za bidhaa

_TARGIN_
_® _
_(Oxycodone Hydrochloride/Naloxone Hydrochloride Controlled Release) _
_Page 1 of 63 _
_ _
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
N
TARGIN
®
Oxycodone Hydrochloride/Naloxone Hydrochloride Controlled Release
Tablets
Tablets, 5/2.5 mg, 10/5 mg, 20/10 mg and 40/20 mg, Oral
Purdue Pharma Standard
Opioid Analgesic
Purdue Pharma
3381 Steeles Avenue East Suite 310
Toronto, ON
M2H 3S7
Date of Initial Authorization:
December 16, 2009
Date of Revision:
January 08, 2024
Submission Control Number: 273393
TARGIN
®
is a trademark of Purdue Pharma
_TARGIN_
_® _
_(Oxycodone Hydrochloride/Naloxone Hydrochloride Controlled Release) _
_Page 2 of 63_
RECENT MAJOR LABEL CHANGES
4 DOSAGE AND ADMINISTRATION, 4.1 Dosing Considerations
10/2023
4 DOSAGE AND ADMINISTRATION, 4.2 Recommended Dose
and Dose Adjustment
10/ 2023
7 WARNING AND PRECAUTIONS, Addiction, Abuse and Misuse
10/2023
7 WARNING AND PRECAUTIONS, Dependence/Tolerance
10/ 2023
7 WARNING AND PRECAUTIONS, Hepatic/Biliary/Pancreatic
10/ 2023
7 WARNING AND PRECAUTIONS, Neurologic
10/ 2023
7 WARNING AND PRECAUTIONS, Reproductive Health: Female
and Male Potential
10/ 2023
7 WARNINGS AND PRECAUTIONS, Respiratory
10/2023
7 WARNING AND PRECAUTIONS, 7.1 Special Populations,
Patients with Hepatic and Renal Impairment
10/ 2023
TABLE OF CONTENTS
RECENT MAJOR LABEL CHANGES
.....................................................................................
2
TABLE OF CONTENTS
..........................................................................................................
2
PART I: HEALTH PROFESSIONAL
INFORMATION...............................................................
4
1
INDICATIONS..............................................................................................................
4
1.1
Pediatrics
...........................................................................................................
4
1.2
Geriatrics...........................................................................................................